Table 1 Demographic and clinical characteristics of patients with P. aeruginosa infection. * P<0.05.
Variable | CRPA (n = 89) | CSPA (n = 89) | Statistic | P |
|---|---|---|---|---|
Sex (male), n (%) | 55 (61.80) | 59 (66.29) | 0.390 | 0.532 |
Age, M (Q₁, Q₃) | 63.00 (52.00,74.00) | 63.00 (52.00,73.00) | 0.003 | 0.998 |
Duration of hospitalization, M (Q₁, Q₃) | 24.00 (17.00, 35.00) | 33.00 (22.00, 56.00) | -4.155 | < 0.001* |
ICU, n (%) | 32 (35.96) | 59 (66.29) | 17.620 | < 0.001* |
Tumor, n (%) | 37 (41.57) | 33 (37.08) | 0.377 | 0.539 |
Diabetes, n (%) | 17 (19.10) | 21 (23.60) | 0.535 | 0.464 |
Hypertension, n (%) | 27 (30.34) | 37 (41.57) | 2.440 | 0.118 |
Cardiovascular disease, n (%) | 20 (22.47) | 18 (20.22) | 0.134 | 0.714 |
Cerebrovascular disease, n (%) | 24 (26.97) | 24 (26.97) | 0.000 | 1.000 |
Renal failure, n (%) | 10 (11.24) | 11 (12.36) | 0.054 | 0.816 |
Respiratory failure, n (%) | 14 (15.73) | 26 (29.21) | 4.643 | 0.031* |
Trauma, n (%) | 25 (28.09) | 20 (22.47) | 0.744 | 0.389 |
Hypoproteinemia, n (%) | 33 (37.08) | 51 (57.30) | 7.304 | 0.007* |
History of surgery, n (%) | 36 (40.45) | 35 (39.33) | 0.023 | 0.878 |
Days of fever, M (Q₁, Q₃) | 4 (2,8) | 12 (8,19) | -6.489 | < 0.001* |
Duration of central venous catheterization, M (Q₁, Q₃) | 15 (0,23) | 25 (16,46) | -5.557 | < 0.001* |
Duration of mechanical ventilation, M (Q₁, Q₃) | 0 (0,4) | 4 (0,17) | -4.483 | < 0.001* |
Retention time of urinary catheter, M (Q₁, Q₃) | 5 (0,16) | 21 (13,30) | -5.956 | < 0.001* |
Indwelling drainage tube, n (%) | 43 (48.31) | 47 (52.81) | 0.360 | 0.549 |
Transfusion, n (%) | 50 (56.18) | 57 (64.04) | 1.148 | 0.284 |
Continuous Renal Replacement Therapy, n (%) | 16 (17.98) | 19 (21.35) | 0.320 | 0.572 |
Puncture surgery, n (%) | 52 (58.43) | 62 (69.66) | 2.440 | 0.118 |
Cephalosporins, n (%) | 77 (86.52) | 75 (84.27) | 0.180 | 0.671 |
Carbapenems, n (%) | 16 (17.98) | 78 (87.64) | 86.656 | < 0.001* |
tetracyclines, n (%) | 13 (14.61) | 30 (33.71) | 8.862 | 0.003* |
glycopeptides, n (%) | 17 (19.10) | 35 (39.33) | 8.802 | 0.003* |
aminoglycosides, n (%) | 38 (42.70) | 44 (49.44) | 0.814 | 0.367 |
Fluoroquinolones, n (%) | 24 (26.97) | 50 (56.18) | 15.635 | < 0.001* |
Linazolamide, n (%) | 8 (8.99) | 23 (25.84) | 8.789 | 0.003* |
Immunosuppressant, n (%) | 5 (5.62) | 16 (17.98) | 6.533 | 0.011* |
antifungal agents, n (%) | 30 (33.71) | 43 (48.31) | 3.925 | 0.048* |
β-lactamase inhibitors, n (%) | 36 (40.45) | 42 (47.19) | 0.822 | 0.365 |
